Chronic severe hepatitis (CSH) can cause
|
|
- Muriel Manning
- 5 years ago
- Views:
Transcription
1 Original Article / Liver The MELD scoring system for predicting prognosis in patients with severe hepatitis after plasma exchange treatment Jian-Wu Yu, Gui-Qiang Wang, Yong-Hua Zhao, Li-Jie Sun, Shu-Qin Wang and Shu-Chen Li Harbin, China BACKGROUND: Hepatic failure caused by severe hepatitis is a clinical syndrome where the major liver functions, particularly detoxification, synthetic functions, and metabolic regulation are impaired to different degrees, and may result in major life-threatening complications such as hepatic encephalopathy, ascites, jaundice, cholestasis, bleeding and hepatorenal syndrome. Plasma exchange (PE) has been found useful in treating patients with fulminant hepatic failure by removing hepatic toxins and replacement of clotting factors, so PE treatment has temporary supportive effects on liver failure caused by severe viral hepatitis. In this study, our aim was to predict the prognosis of patients with severe hepatitis after PE treatment using the end-stage liver disease (MELD) scoring system. METHODS: Two hundred and twenty patients were randomly divided into PE and control groups, and the was calculated for each patient according to the original formula. The efficacy of PE was assessed by or improvement in biochemical parameters and. RESULTS: The levels of total bilirubin and international normalised ratio (INR) in patients whose s were between 30 and 39 were lower than those before PE treatment, as those in patients whose s were 40 Author Affiliations: Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Harbin , China (Yu JW, Zhao YH, Sun LJ, Wang SQ and Li SC); and Department of Infectious Diseases, First Hospital of Peking University, Beijing , China (Wang GQ) Corresponding Author: Shu-Chen Li, MD, Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Harbin , China (Tel: ; Fax: ; shuchenli@yahoo.com.cn) 2007, Hepatobiliary Pancreat Dis Int. All rights reserved. or higher. The of patients in the PE group with s from 30 to 39 was 50.0%, while it was 83.3% in the control group (P<0.01). The of patients with s higher than 40 was 90.0% in the PE group and 98.0% in the control group (P>0.05). CONCLUSIONS: PE treatment can decrease the serum total bilirubin level and INR and of patients with severe hepatitis and improve liver function. Compared with the control group, PE can significantly decrease the of patients with s from 30 to 39, but has no effect in patients with s of 40 or higher. (Hepatobiliary Pancreat Dis Int 2007; 6: ) KEY WORDS: severe hepatitis; model for end-stage liver disease; plasma exchange; Introduction Chronic severe hepatitis (CSH) can cause irreversible hepatic failure resulting from the severe impairment of liver function, and is associated with a rate of over 70% if liver transplantation is not available. [1] Liver failure is the clinical syndrome that results from severe impairment of liver function. This syndrome encompasses the development of encephalopathy, coagulopathy, jaundice, and hepatorenal syndrome. [2] Plasma exchange (PE) is efficacious in removing toxic substances which accumulate in patients with fulminant hepatic failure (evidenced by a decrease in plasma ammonia, bilirubin and bile acid levels), halting the progression of liver injury (as shown by decreased plasma alanine aminotransferase and lactate dehydrogenase levels), retaining useful materials (evidenced by higher hepatocyte growth factor retention), improving liver function (as shown 492 Hepatobiliary Pancreat Dis Int,Vol 6,No 5 October 15,2007
2 The MELD scoring system for predicting prognosis in patients with severe hepatitis after PE treatment by a better indocyanine green clearance value), promoting liver regeneration, and prolonging survival of patients. [3] PE is one of the reliable therapies for patients with CSH, but the reported efficacy is very different. Forman et al [4] reported that the model for end-stage liver disease (MELD) score is related to the prognosis of patients with severe hepatitis. In this study, we used the MELD scoring system to predict the 3-month prognosis of patients with CSH after PE treatment. Methods Patients Two hundred and twenty hospitalized patients with CSH were recruited from the Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, China, between January 2003 and December They were randomly divided into two groups (PE and control groups). The 110 patients in the PE group included 90 males and 20 females, with an average age of 44.0±10.3 years, while the 110 patients in the control group included 88 males and 22 females, with an average age of 45.9±10.9 years. The diagnosis of CSH patients was according to the criteria of the National Infectious Diseases Meeting in Xi'an [5] According to these criteria, there are three types of severe viral hepatitis in China: acute, subacute, and chronic-severe. Acute-severe hepatitis is characterized by malignant jaundice (total bilirubin >171 μmol/l), hepatic encephalopathy (above phase II), prolonged prothrombin time (prothrombin activity <40%), extreme fatigue, loss of appetite, nausea, abdominal distention or ascites and bleeding tendency within two weeks after the clinical manifestations. Subacute-severe hepatitis is characterized by symptoms of acute-severe hepatitis from two weeks to six months. Chronicsevere hepatitis is clinically similar to subacutesevere hepatitis on the basis of known history as a HBV or HCV carrier, chronic hepatitis or cirrhosis, signs of chronic liver disease (such as liver palmer or spider angioma) or with results from imaging or biopsy indicating the existence of chronic hepatitis. Malignant jaundice induced by obstructive jaundice and hemolytic jaundice and prolonged prothrombin time induced by blood system disease were excluded. Drug hepatitis, Wilson disease, alcoholic liver disease, and autoimmune hepatitis were also excluded. Of the 220 patients with CSH, 198 were hepatitis B virus positive, 22 were non-a-g hepatitis virus positive. Before treatment, 23 patients had encephalopathy, 21 had spontaneous bacterial peritonitis and 6 had hepatorenal syndrome. Therapeutic methods The 110 patients in the control group were given standard medical treatment. This included absolute bed rest; supplement of energy and vitamins; intravenous drop infusion of hepatocyte growthpromoting factors, transmetil, prostaglandin E, albumin, plasma, and prothrombin complex; maintenance of water, electrolyte and acid-base equilibrium; and prevention and treatment of complications. The patients with severe hepatitis B (HBV DNA copies/ml) were treated with lamivudine, 100 mg daily. The 110 patients in the PE group were given standard medical treatment combined with PE therapy. All patients offered written informed consent before treatment. The PE treatment room was thoroughly sterilized by UV light. Before PE treatment, blood access for extracorporeal circulation was established with a double-lumen catheter inserted into the patient's jugular and femoral veins, and heparin was used to block the catheter after every session. PE was performed using the WLXGX-8888 WeiLi Plasmapheresis-Artificial Liver Support System, a matched plasma separator (WLXGX-8888) and channels (Beijing WeiLi Co., Ltd.). Routinely before therapy, 5 mg dexamethasone (i.v.) and 25 mg diprazine (i.m.) were injected to prevent an allergic response. During each session of PE treatment, which lasted for 4-6 hours, the total volume of exchanged plasma was ml. The flow rate of blood was adjusted to ml/min, and the flow rate of filtration was adjusted to ml/min. The ratio of filtration pump to blood pump was During the session, the prothrombin time was tested constantly to allow the dose of heparin to be adjusted. Blood pressure, pulses and ECG were recorded continuously. Transmembrane, arterial and venous pressures were closely watched, and dexamethasone and calcium gluconate were used routinely during sessions. Five-ten mg heparin was injected routinely before therapy, and the total dose of heparin was 5-25 mg. Protamine was not used during sessions. PE therapy was carried out twice every week. For patients at the critical stage, PE therapy was carried out daily or every other day until the patient's condition was stable. [6] Parameters The level of serum creatinine, the international normalised ratio (INR) for prothrombin time, and the Hepatobiliary Pancreat Dis Int,Vol 6,No 5 October 15,
3 Hepatobiliary & Pancreatic Diseases International Table 1. Comparison of clinical and biochemical characteristics and s of patients in the PE and control groups s Gender (M/F) Age (yrs) n INR Creatinine (μmol/l) Total bilirubin (μmol/ L) ALT (U/L) AST (U/L) Albumin (g/l) MELD score Days of hospital stay PE 50/ ± ± ± ± ± ± ± ± ±6.9 Control 47/ ± ± ± ± ± ± ± ± ±7.2 s 40 PE 40/ ± ± ± ± ± ± ± ± ±5.4 Control 41/9 44.1± ± ± ± ± ± ± ± ±6.0 Compared with the control group, P>0.05. level of serum total bilirubin of each CSH patient were recorded. The was calculated according to the original formula proposed by the Mayo Clinic group: 3.8 log e [bilirubin (mg/dl)]+11.2 log e (INR)+ 9.6 log e [creatinine (mg/dl)]+6.4 (etiology: 0 if cholestatic or alcoholic, 1 otherwise). [7] Clinical and biochemical characteristics Blood samples were collected before and 24 hours after each treatment to check liver function, renal function, INR and routine blood tests. The results of the clinical data and s before and after PE treatment were compared. Analysis of The 220 patients with CSH were followed up for at least three months. The outcome (recovery, bridging to liver transplantation, or death) of each patient was recorded. Statistical analysis The clinical and biochemical characteristics and s of the patients are expressed as mean± SD. Analysis of used the Chi-square test, the comparison of the clinical data and s before and after PE treatment used Student's t test, and for all analyses a P value less than 0.05 was considered statistically significant. Results Clinical and biochemical parameters and MELD scores of patients with and without PE treatment The s of all the patients were over 30. The patients were divided into two groups according to their scores: 30-39, and 40. There was no significant difference between the PE and control groups in clinical and biochemical characteristics and MELD scores (Table 1). Table 2. Clinical data and of patients pre- and post-pe treatment Patients in PE group Total bilirubin (μmol/l) INR Creatinine (μmol/ L) MELD score Pre-PE treatment 549.3± ± ± ±3.8 Post-PE treatment 422.8±53.1 * 3.0±0.3 * 153.7±42.0 # 37.6±3.7 * s Pre-PE treatment 507.7± ± ± ±3.5 Post-PE treatment 380.4±40.6 * 2.4±0.3 * 109.4±22.7 # 30.6±3.7 * s 40 Pre-PE treatment 651.6± ± ± ±4.2 Post-PE treatment 593.7±60.8 * 3.7±0.4 * 142.8±25.1 # 39.4±3.6 * *: Compared with pre-treatment, P<0.05; #: compared with pretreatment, P>0.05. Table 3. Relationship between and 3-month Overall Mortality of patients with Mortality of patients with 40 PE 68.2 (75/110) * 50.0 (30/60) ** 90.0 (45/50) # Control 90.0 (99/110) 83.3 (50/60) 98.0 (49/50) *: Compared with the control group, χ 2 =15.832, P<0.01; **: compared with the control group, χ 2 =15.00, P<0.01; #: compared with the control group, χ 2 =2.837, P>0.05. Clinical and biochemical characteristics and MELD scores after PE treatment The levels of total bilirubin and INR in patients whose s were between 30 and 39 were significantly lower than those before PE treatment, as were the levels in patients with s 40 (Table 2). The levels of serum creatinine were low before PE treatment, but there was no significant difference afterwards, which may be due to PE treatment with little effect on renal function in CSH patients. There was no significant difference in the 494 Hepatobiliary Pancreat Dis Int,Vol 6,No 5 October 15,2007
4 The MELD scoring system for predicting prognosis in patients with severe hepatitis after PE treatment levels of white blood cells, red blood cells, hemoglobin and platelets before and after therapy. Renal electrolytes showed no significant changes pre- and post-treatment. Mortality in patients with and without PE treatment During the 3-month follow-up, 174 patients died. The causes of death were all related to liver disease: 82 patients died of hepatic encephalopathy, 38 of hepatorenal syndrome, 42 of variceal bleeding; and 11 of sepsis due to liver dysfunction. Six patients bridged to liver transplantation, of whom one died during follow-up because of liver failure. The of patients in the PE group with s from 30 to 39 was 50.0%, while it was significantly higher (83.3%) in the control group (χ 2 =15.000, P<0.01). The of patients with s 40 was 90.0% in the PE group and 98.0% in the control group, showing no significant difference (χ 2 =2.837, P>0.05) (Table 3). PE treatment significantly decreased the of patients with s from 30 to 39, but had no effect on patients with s 40. Discussion In patients with CSH, the massive accumulation of metabolic toxins such as middle or micromolecule substitutes (blood ammonia, direct bilirubin, indirect bilirubin and aromatic amino acids), and macromolecule substitutes (benzopyrrole, mercaptan and endotoxin) in the circulation delays the recovery of hepatic function and causes many kinds of severe complications, which progress to hepatic failure. [8] PE treatment being the most common non-bioartificial liver has been widely applied in clinical treatment. PE separates and discards the plasma to remove the toxic substances (especially those binding with proteins) and compensates with an identical volume of normal freshfrozen plasma to supplement essential substances such as coagulation factors, albumin and immunoglobin so as to ameliorate the microenvironment of the liver and accelerate liver regeneration and functional [9, 10] recovery. Our study showed that PE treatment decreased the serum total bilirubin level and INR and in patients with severe hepatitis and improving liver function, which further suggested that PE can temporarily support liver function and gain precious time for hepatocytes to regenerate and thus decrease the of patients with CSH. At present, prediction of the prognosis in patients with CSH is largely limited to small-sample and single factor studies, with few objective parameters. The reports about clinical and biochemical characteristics and of patients with CSH after PE treatment [11, 12] are conflicting. The MELD was formulated to predict 3-month for cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt. [13] In the United States, the MELD scoring system is mainly used in patients with end-stage cirrhosis awaiting liver transplantation. [14] At present, the MELD has been validated by the same authors on a broad series of patients with liver diseases of various etiology and severity. [15] The takes into consideration objective parameters (serum creatinine, INR for prothrombin time and bilirubin levels) and is computed with statistically derived coefficients on a continuous scale with no upper or lower limits, thus avoiding many drawbacks of the Child-Pugh score. [16] The short-term survival rates of patients with endstage liver disease decrease gradually as the increases. [7] This MELD scoring system is not only objective, but also consistent with the characteristics of CSH (for example, hyperbilirubinemia, coagulopathy, and renal function failure), so it may be used to predict the prognosis of CSH patients. [17] We studied the 3-month prognosis of patients with severe hepatitis after PE treatment using the MELD scoring system. The 3-month of patients with scores of given standard medical treatment was 83%, while for those given PE, it was 50.0%, suggesting that PE significantly increased the shortterm survival rate of these patients, so PE treatment and other artificial liver support system therapy should be started as early as possible. The 3-month of the patients with s 40 given standard medical treatment was 98%, whereas for those given PE, it was 90.0%, suggesting that PE did not significantly increase the short-term survival rate in these patients. Liver transplantation may be the only effective therapeutic modality to save these patients' lives. While awaiting liver transplantation, PE treatment's temporary support of liver function is expected to be effective to reduce metabolic disturbance and coagulopathy, improve liver function before operation, and increase the success rate of the operation and survival rate of patients. In conclusion, PE treatment decreases the serum total bilirubin level as well as INR and s of patients with fulminant hepatitis and improves liver function. Compared with controls, PE can significantly decrease the of patients with s from 30 to 39, but it is not effective in patients with s 40. Hepatobiliary Pancreat Dis Int,Vol 6,No 5 October 15,
5 Hepatobiliary & Pancreatic Diseases International Funding: This study was supported by a grant from the Science and Technology Research Foundation of the Department of Education, Heilongjiang Province, China (No ). Ethical approval: Not needed. Contributors: YJW and LSC proposed the study and YJW wrote the first draft. SLJ analyzed the data. All authors contributed to the design and interpretation of the study and to further drafts. LSC is the guarantor. Competing interest: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. References 1 Marrero J, Martinez FJ, Hyzy R. Advances in critical care hepatology. Am J Respir Crit Care Med 2003;168: Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005;41: Ho DW, Fan ST, To J, Woo YH, Zhang Z, Lau C, et al. Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model. Gut 2002;50: Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo Endstage Liver Disease. Hepatology 2001;33: Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for viral hepatitis. Zhonghua Chuan Ran Bing Za Zhi 2001;19: Artificial Liver Chinese Association of Infectious and Parasitic Diseases. Operating guide for artificial liver support system. Zhonghua Gan Zang Bing Za Zhi 2002;10: Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: Mullin EJ, Metcalfe MS, Maddern GJ. Artificial Liver Support: potential to retard regeneration? Arch Surg 2004;139: Nakae H, Yonekawa T, Narita K, Endo S. Are proinflammatory cytokine concentrations reduced by plasma exchange in patients with severe acute hepatic failure? Res Commun Mol Pathol Pharmacol 2001;109: Nakamura T, Ushiyama C, Suzuki S, Shimada N, Ebihara I, Suzaki M, et al. Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis. Blood Purif 2000;18: Shang J, Jia BL, Zhang HP, Chen P, Jin X. Effects of artificial liver support system on chronic sever hepatitis patients. Zhonghua Gan Zang Bing Za Zhi 2003;11: Li L, Yang Q, Huang J, Xu X, Chen Y, Chen Y, et al. Treatment of hepatic failure with artificial liver support system. Chin Med J (Engl) 2001;114: Fejfar T, Safka V, Hulek P, Vanasek T, Krajina A, Jirkovsky V. in prediction of early in patients suffering refractory ascites treated by TIPS. Vnitr Lek 2006; 52: Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8: Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts in patients with alcoholic hepatitis. Hepatology 2005;41: Huo TI, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, et al. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl 2006;12: Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system. J Gastroenterol Hepatol 2006;21: Received March 12, 2007 Accepted after revision June 25, Hepatobiliary Pancreat Dis Int,Vol 6,No 5 October 15,2007
Acute liver failure (ALF) is a rapidly progressive
ICGR15 Original evaluates Article the / Liver short-term prognosis of ALF Indocyanine green clearance test combined with MELD score in predicting the short-term prognosis of patients with acute liver failure
More informationDifferent models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure
ORIGINAL ARTICLE Short-term prognosis of patients with HBV-related ACLF., 2012; 11 (3): 311-319 May-June, Vol. 11 No.3, 2012: 311-319 311 Different models in predicting the short-term prognosis of patients
More informationThe MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality
The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality Sammy Saab, 1,2 Carmen Landaverde, 3 Ayman B Ibrahim, 2 Francisco Durazo, 1,2 Steven Han, 1,2 Hasan
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationORIGINAL ARTICLE Gastroenterology & Hepatology INTRODUCTION
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.8.1207 J Korean Med Sci 2013; 28: 1207-1212 The Model for End-Stage Liver Disease Score-Based System Predicts Short
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationHepatitis B virus (HBV) has a high prevalence
Plasma Original exchange Article to / Liver treat ACLF in China Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-onchronic liver failure: a nationwide prospective
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationWEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
More informationAlcoholic hepatitis (AH) is an acute, inflammatory. MELD Accurately Predicts Mortality in Patients With Alcoholic Hepatitis
MELD Accurately Predicts Mortality in Patients With Alcoholic Hepatitis Winston Dunn, 1 Laith H. Jamil, 1 Larry S. Brown, 2 Russell H. Wiesner, 1 W. Ray Kim, 1 K. V. Narayanan Menon, 1 Michael Malinchoc,
More informationCurrent Concepts in Diagnosis and Management of Acute Liver Failure
Current Concepts in Diagnosis and Management of Acute Liver Failure Oren Fix, MD, MSc, FACP, AGAF, FAASLD Medical Director, Liver Transplant Program Swedish Medical Center Seattle, WA Learning Objectives
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationChild-Pugh Score Predicts Mortality Better than Model of End Stage Liver Disease: A Study in a Tertiary Care Hospital in the Periphery of Karachi
Original Article Child-Pugh Score Predicts Mortality Better than Model of End Stage Liver Disease: A Study in a Tertiary Care Hospital in the Periphery of Karachi Ashok Kumar 1, Ajeet Kumar 2, Syeda Urooj
More informationKing Abdul-Aziz University Hospital (KAUH) is a tertiary
Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationDiseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:
Diseases of liver Dr. Mohamed. A. Mahdi Mob: 0123002800 4/2/2019 Cirrhosis Cirrhosis is a complication of many liver disease. Permanent scarring of the liver. A late-stage liver disease. The inflammation
More informationORIGINAL ARTICLE. Jun Zheng 1, Rong-chun Xing 1, Wei-hong Zheng 2, Wei Liu 1, Ru-cheng Yao 1, Xiao-song Li 1, Jian-ping Du 1, Lin Li 1.
JBUON 2017; 22(3): 709-713 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A comparative study on postoperative mortality prediction of SFLI scoring
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationAlbumin-to-bilirubin score for assessing the in-hospital death in cirrhosis
Original Article Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis Lichun Shao 1 *, Bing Han 1 *, Shu An 2, Jiaxin Ma 1, Xiaozhong Guo 3, Fernando Gomes Romeiro 4, Andrea Mancuso
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationT here is an increasing discrepancy between the number of
134 LIVER DISEASE MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study F Botta, E Giannini, P Romagnoli,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationAssessment of Liver Function: Implications for HCC Treatment
Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationInt J Clin Exp Med 2015;8(4): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(4):5989-5998 www.ijcem.com /ISSN:1940-5901/IJCEM0006112 Original Article Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis: a retrospective
More informationRisk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis
Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong
More informationLiver Transplantation
1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationDISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
More informationApproach to the Patient with Liver Disease
Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases
More informationORIGINAL RESEARCH. Abstract
ORIGINAL RESEARCH Yu-Bao Zheng PhD, MD Dong-Ying Xie PhD, MD Yu-Rong Gu MD Ying Yan MD Ze-Bin Wu MD Zi-Ying Lei MD Liang Peng PhD, MD Shi-Bin Xie PhD, MD Zhi-liang Gao PhD, MD Wei-min Ke MD Department
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationAcute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
More informationSurvival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation
American Journal of Transplantation 2008; 8: 2537 2546 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationPredicting Outcome After Cardiac Surgery in Patients With Cirrhosis: A Comparison of Child Pugh and MELD Scores
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:719 723 Predicting Outcome After Cardiac Surgery in Patients With Cirrhosis: A Comparison of Child Pugh and MELD Scores AMITABH SUMAN,* DAVID S. BARNES,*
More informationCrackCast Episode 28 Jaundice
CrackCast Episode 28 Jaundice Episode overview: 1) Describe heme metabolism 2) List common pre-hepatic/hepatic/post-hepatic causes of jaundice Wisecracks: 1) What are clinical signs of liver disease? 2)
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationPredictors of Mortality in Long-Term Follow-Up of Patients with Terminal Alcoholic Cirrhosis: Is It Time to Accept Remodeled Scores?
Original Paper Received: March 8, 2015 Accepted: September 27, 2016 Published online: September 27, 2016 Predictors of Mortality in Long-Term Follow-Up of Patients with Terminal Alcoholic Cirrhosis: Is
More informationUpdate in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
More informationLiver Disease. By: Michael Martins
Liver Disease By: Michael Martins Recently I have been getting a flurry of patients that have some serious liver complications. This week s literature review will be the dental management of the patients
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationLiver Failure. The most severe clinical consequence of liver disease is liver failure:
Liver diseases I The major primary diseases of the liver are: - Viral hepatitis, - Nonalcoholic fatty liver disease (NAFLD), - Alcoholic liver disease, - Hepatocellular carcinoma (HCC) Hepatic damage also
More informationPathological Features and Prognosis in Chronic Hepatitis B Virus Carriers
The Journal of International Medical Research 2011; 39: 71 77 Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs Hassanein T, Oliver D, Stange J, Steiner C Record Status This is a critical
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationWorld Health Organization. Western Pacific Region
Basic modules for hepatitis 1 Basic Module 1 Liver anatomy and physiology 2 Position of liver Midline Located in right upper abdomen Protected by the right rib cage Right upper Measures: 12 15 cm in vertical
More informationDefinition: fibrosis and nodular regeneration resulting from hepatocellular injury
Cirrhosis Understanding the liver: Patterns of LFT Abnormalities - Hepatocellular/Transaminitis: o Ratio of AST: ALT >2:1 ETOH (keep in mind AST is also produced by red cells, heart muscle) o If Aminotransferases
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Scott W. Biggins, MD, MAS Assistant Professor Division of Gastroenterology UCSF Scott.Biggins@ucsf.edu (Thanks to Hal Yee, MD) This Morning s Presentation Clinical vignettes
More informationClinical presentation and predictors of survival in patients with Budd Chiari Syndrome: Experience from a tertiary care hospital in Pakistan
120 ORIGINAL ARTICLE Clinical presentation and predictors of survival in patients with Budd Chiari Syndrome: Experience from a tertiary care hospital in Pakistan Abbas Ali Tasneem, Ghous Bux Soomro, Zaigham
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationInterpreting Liver Tests What Do They Mean? Roman E. Perri, MD
Interpreting Liver Tests What Do They Mean? Roman E. Perri, MD The assessment of patients with abnormal liver tests is common in both primary care and gastroenterology clinics. However, among patients
More informationPathophysiology I Liver and Biliary Disease
Pathophysiology I Liver and Biliary Disease The Liver The liver is located in the right upper portion of the abdominal cavity just beneath the right side of the rib cage. The liver has many functions that
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationIn the United States, the Model for End-Stage Liver. Re-weighting the Model for End-Stage Liver Disease Score Components
GASTROENTEROLOGY 2008;135:1575 1581 Re-weighting the Model for End-Stage Liver Disease Score Components PRATIMA SHARMA,* DOUGLAS E. SCHAUBEL,, CAMELIA S. SIMA,, ROBERT M. MERION,, and ANNA S. F. LOK* *Division
More informationAlpha-1 Antitrypsin Deficiency: Liver Disease
Alpha-1 Antitrypsin Deficiency: Liver Disease Who is at risk to develop Alpha-1 liver disease? Alpha-1 liver disease may affect children and adults who have abnormal Alpha-1 antitrypsin genes. Keys to
More informationAbnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University
Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose
More informationAssociation of vitamin-d levels with the severity of liver disease
Original article: Association of vitamin-d levels with the severity of liver disease Jayagowri Karthikeyan, Sujatha Rajaragupathy Department of Biochemistry, PSG Institute of medical sciences and research,
More informationSeverity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales
International Journal of Advanced Biotechnology and Research (IJABR) ISSN 0976-2612, Online ISSN 2278 599X, Vol-10, Issue-1, 2019, pp519-524 http://www.bipublication.com Research Article Severity and Mortality
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationCHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
More informationSubmitted: Revised: Published:
ORIGINAL ARTICLE ASIAN JOURNAL OF MEDICAL SCIENCES A comparative study of albumin-bilirubin score, MELD and Child Pugh scores for predicting the in-hospital mortality in cirrhotic patients complicated
More informationDeath in patients waiting for liver transplantation. Liver Transplant Recipient Selection: MELD vs. Clinical Judgment
ORIGINAL ARTICLES Liver Transplant Recipient Selection: MELD vs. Clinical Judgment Michael A. Fink, 1,2 Peter W. Angus, 1 Paul J. Gow, 1 S. Roger Berry, 1,2 Bao-Zhong Wang, 1,2 Vijayaragavan Muralidharan,
More informationInt J Clin Exp Med 2016;9(6): /ISSN: /IJCEM
Int J Clin Exp Med 2016;9(6):10364-10373 www.ijcem.com /ISSN:1940-5901/IJCEM0023853 Original Article Early bilirubin response in acute-on-chronic hepatitis B liver failure patients treated with corticosteroids
More informationA lcoholic hepatitis is perhaps the most florid manifestation
1174 ALCOHOLIC LIVER DISEASE Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score E H Forrest, C D J Evans, S Stewart,
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationB C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
More informationSERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES
SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationThirty-day hospital readmission rates frequently are used as
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:254 259 Incidence and Predictors of 30-Day Readmission Among Patients Hospitalized for Advanced Liver Disease KENNETH BERMAN,*, SWETA TANDRA,* KATE FORSSELL,
More informationDevelopment of the Allocation System for Deceased Donor Liver Transplantation
Clinical Medicine & Research Volume 3, Number 2: 87-92 2005 Marshfield Clinic http://www.clinmedres.org Review Development of the Allocation System for Deceased Donor Liver Transplantation John M. Coombes,
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Professor of Medicine University of Chicago Chicago, Illinois Overview Initial assessment of liver disease How do you diagnose cirrhosis?
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationCHAPTER 7. End Stage Liver Disease in the ICU: Walking a Tightrope. Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing
CHAPTER 7 End Stage Liver Disease in the ICU: Walking a Tightrope Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing Besey Oren, Assistant Professor Istanbul University Health
More informationSupplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1
Supplemental Tables Supplemental Table 1 Various etiologies of liver cirrhosis and their association with liver stiffness and AST/ALT ratio Disease category Cause Example LS AST/ALT Inflammatory liver
More information